

Applicant : Sara Lavi
Serial No.: 09/029,479
Filed : October 21, 1998
Page 2

application.

Please add new claims 77-91 as follows:

- C1
77. (New) A method for treating a mammalian subject afflicted with cancer which comprises administering to the subject a vector comprising adeno-associated virus (AAV) or a portion thereof in an amount effective to treat the cancer in the subject, so as to thereby treat the subject.
 78. (New) The method of claim 77, wherein the portion of AAV comprises a nucleic acid having the nucleotide sequence set forth in SEQ. ID. NO:13.
 79. (New) The method of claim 77, wherein the portion of AAV comprises a nucleic acid having the nucleotide sequence set forth in SEQ. ID. NO:14.
 80. (New) The method of claim 77, wherein the vector further comprises a nucleic acid encoding PP2C α .
 81. (New) The method of claim 77, wherein the vector further comprises a nucleic acid encoding a PP2C α antisense nucleic acid.
 82. (New) A method for treating a mammalian subject afflicted with colon cancer which comprises administering to the subject a vector comprising an expression control sequence operably linked to a nucleic acid encoding PP2C α in an amount effective to increase the level of PP2C α in the cytoplasm of the subject's cancerous colon cells, so as to thereby treat the subject.

Applicant : Sara Lavi
Serial No.: 09/029,479
Filed : October 21, 1998
Page 3

83. (New) A method for treating a mammalian subject afflicted with invasive breast cancer which comprises administering to the subject a vector comprising an expression control sequence operably linked to a nucleic acid encoding PP2C α in an amount effective to increase the amount of PP2C α in the cytoplasm of the subject's cancerous breast cells, so as to thereby treat the subject.
84. (New) A method for treating a mammalian subject afflicted with noninvasive breast cancer which comprises administering to the subject a vector comprising an expression control sequence operably linked to a nucleic acid encoding a PP2C α antisense nucleic acid in an amount effective to reduce the amount of PP2C α in the cytoplasm of the subject's cancerous breast cells, so as to thereby treat the subject.
85. (New) A method for treating a mammalian subject afflicted with liver cancer which comprises administering to the subject a vector comprising an expression control sequence operably linked to a nucleic acid encoding PP2C α in an amount effective to increase the level of PP2C α in the cytoplasm of the subject's cancerous liver cells, so as to thereby treat the subject.
86. (New) The method of any one of claims 77, 82, 83, 84 and 85, wherein the mammal is a human.
87. (New) The method of any one of claims 77, 82, 83, 84 and 85, wherein PP2C α is human PP2C α .
88. (New) The method of any one of claims 77, 82, 83, 84 and 85,

Applicant : Sara Lavi
Serial No.: 09/029,479
Filed : October 21, 1998
Page 4

wherein the method of administering the vector to the subject is selected from the group consisting of stable transfection, electroporation, transient transfection, lipofection and local inoculation.

89. (New) The method of any one of claims 77, 82, 83, 84 and 85, wherein the vector further comprises at least one targetor moiety.
90. (New) The method of claim 89, wherein the targetor moiety is a receptor.
91. (New) The method of claim 89, wherein the targetor moiety is a ligand.

REMARKS

Claims 65 and 68-76 are pending and under examination in the subject application. Applicant has hereinabove canceled claims 65 and 68-76 without prejudice and added new claims 77-91. New claims 77-91 have been added to more fully claim that which applicant regards as her invention. Support may be found inter alia in the specification as follows: claim 77: page 21, lines 10-15 and line 33; Example 7; claim 78: page 50, line 30 - page 51, line 1; claim 79: page 50, line 30 - page 51, line 3; claim 80: page 16, lines 6-8; claim 81: page 16, lines 6-8; page 17, lines 20-26 and page 48, lines 19-20; claim 82: page 21, line 33; Example 5 on page 45, line 14 - page 46, line 24 and page 46, line 30 - page 47, line 13; claim 83: page 21, line 33; Example 4 on page 44, line 23 - page 45, line 12 and page 46, line 30 - page 47, line 13; claim 84: page 17, lines 20-26; page 21, line 33; Example 4 on page 44, line 23 - page 45, line 12 and page 46, line 30 - page 47, line 13; page 44,